November 19, 2026
Elite Diagnostic Limited (ELITE) has advised that the Board has completed its review of the revised Take-Over Bid Circular dated November 10, 2026, received by the Company on November 11, 2026, with its independent financial adviser and legal adviser.
ELITE has further advised that the Jamaica Stock Exchange (“JSE”) Junior Market Rules require that the Directors’ Circular be approved by the JSE before it is published. The Company has submitted the Draft Directors’ Circular to the JSE and the Financial Services Commission (“FSC”) for review. That review has not yet been completed. The Company will issue the Directors’ Circular promptly once the required approval is received. It will be published on the JSE’s website at www.jamstockex.com and dispatched to shareholders. The Board expects this to be on or about November 24, 2026.
For further details, visit www.jamstockex.com
Disclaimer:
Analyst Certification -The views expressed in this research report accurately reflect the personal views of Mayberry Investments Limited Research Department about those issuer (s) or securities as at the date of this report. Each research analyst (s) also certify that no part of their compensation was, is, or will be, directly or indirectly, related to the specific recommendation(s) or view (s) expressed by that research analyst in this research report.
Company Disclosure -The information contained herein has been obtained from sources believed to be reliable, however its accuracy and completeness cannot be guaranteed. You are hereby notified that any disclosure, copying, distribution or taking any action in reliance on the contents of this information is strictly prohibited and may be unlawful. Mayberry may affect transactions or have positions in securities mentioned herein. In addition, employees of Mayberry may have positions and effect transactions in the securities mentioned herein.